AIA Group Ltd Invests $2.48 Million in Agilent Technologies, Inc. $A

Key Points

• AIA Group Ltd opened a new position in Agilent Technologies in Q3, buying 19,283 shares worth about $2.48 million, per its latest 13F filing.
• Several other institutions materially increased stakes—Fenimore Asset Management added 405,620 shares (a 224.2% rise), while CCLA and Envestnet own roughly 1.03M and 607.9K shares respectively.
• Analyst sentiment is broadly positive with a MarketBeat average rating of "Moderate Buy" and an average price target of $161.20, though individual targets range as high as $185.00.

AIA Group Ltd acquired a new position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 19,283 shares of the medical research company's stock, valued at approximately $2,475,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Bridgefront Capital LLC acquired a new stake in shares of Agilent Technologies during the 3rd quarter valued at $1,323,000. Envestnet Asset Management Inc. grew its position in Agilent Technologies by 3.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 607,914 shares of the medical research company's stock worth $78,026,000 after acquiring an additional 22,498 shares during the last quarter. CCLA Investment Management increased its holdings in Agilent Technologies by 10.5% in the 3rd quarter. CCLA Investment Management now owns 1,027,970 shares of the medical research company's stock worth $131,909,000 after purchasing an additional 97,312 shares in the last quarter. Osaic Holdings Inc. raised its position in Agilent Technologies by 35.5% in the second quarter. Osaic Holdings Inc. now owns 68,053 shares of the medical research company's stock valued at $8,017,000 after purchasing an additional 17,817 shares during the last quarter. Finally, Fenimore Asset Management Inc raised its position in Agilent Technologies by 224.2% in the third quarter. Fenimore Asset Management Inc now owns 586,500 shares of the medical research company's stock valued at $75,277,000 after purchasing an additional 405,620 shares during the last quarter.

Analysts Set New Price Targets

A has been the topic of several research reports. JPMorgan Chase & Co. boosted their price target on Agilent Technologies from $165.00 to $180.00 and gave the stock an "overweight" rating in a report on Tuesday, November 25th. Morgan Stanley dropped their price objective on shares of Agilent Technologies from $180.00 to $160.00 and set an "overweight" rating for the company in a report on Tuesday, March 3rd. Weiss Ratings reiterated a "hold (c+)" rating on shares of Agilent Technologies in a research report on Monday, December 29th. Citigroup upped their price target on shares of Agilent Technologies from $165.00 to $185.00 and gave the company a "buy" rating in a research report on Tuesday, November 25th. Finally, HSBC started coverage on shares of Agilent Technologies in a research note on Tuesday, January 20th. They set a "buy" rating and a $180.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Agilent Technologies has an average rating of "Moderate Buy" and an average price target of $161.20.

Agilent Technologies Stock Up 0.2%

Agilent Technologies stock opened at $111.68 on Friday. The company has a market capitalization of $31.56 billion, a PE ratio of 24.65, a PEG ratio of 2.35 and a beta of 1.31. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $160.27. The firm's fifty day moving average is $127.62 and its 200 day moving average is $135.43. The company has a quick ratio of 1.59, a current ratio of 2.07 and a debt-to-equity ratio of 0.44.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing analysts' consensus estimates of $1.37 by ($0.01). Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The company had revenue of $1.80 billion during the quarter, compared to analyst estimates of $1.81 billion. During the same quarter in the previous year, the business posted $1.31 earnings per share. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. As a group, sell-side analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.255 per share. The ex-dividend date is Tuesday, March 31st. This represents a $1.02 annualized dividend and a yield of 0.9%. Agilent Technologies's dividend payout ratio is presently 22.52%.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.